New drug – MIV-711 – may reduce disease progression
A potential arthritis drug of interest to experts seems to reduce bone and cartilage progression and appears to be safe, a team reports in Annals of Internal Medicine.
MIV-711 inhibits an enzyme called cathepsin K that degrades key components of bone and cartilage, so the research team decided to look at if it could help people with knee osteoarthritis. They split people with primary knee osteoarthritis into groups for 26 weeks:
- 82 people were given 100mg/day of MIV-711;
- 81 people were given 200mg/day of MIV-711;
- 77 people were given a placebo.
The new drug did not improve pain levels. But it did “significantly reduce bone and cartilage progression with a reassuring safety profile”. Although nine serious adverse events occurred in six people, none were considered to be treatment-related.
The success of the study means that MIV-711 will receive further attention as a potential disease-modifying osteoarthritis drug – good news for people with arthritis.
Click here to read the original research.
Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2019.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.